Expert Interview
A Second Look: Reviewing the potential of the CanGaroo RM Antibacterial Envelope from Aziyo Biologics in light of its 'Not Substantially Equivalent determination' from the FDA
Ticker(s): AZYO, MDTInstitution: UPMC Heart and Vascular Institute
- Cardiologist and Critical Care Physician at UPMC, board certified in Cardiovascular Medicine, Critical Care Medicine, Echocardiography, and Nuclear Cardiology.
- Treats 500 patients with hypertension per year. Refers 50 patients for transvenous devices every month and is familiar with the CanGaroo and TYRX envelopes.
- Clinical interests include structural echocardiography, critical care cardiology, and critical care echocardiography.
Please describe your background and practice setting.
Added By: ben_adminHow many cardiac implantable electronic devices do you implant on a monthly basis?
Added By: ben_adminHow many of the CanGaroo envelopes have you utilized in the past 12 months?
Added By: ben_adminWhat is your opinion on the next generation device, utilizing rifampin and minocycline for bacterial protection?
Added By: ben_adminWhat do you think of the 'Not Substantially Equivalent determination' from the FDA? How will it impact the future of this envelope?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
